Compass Therapeutics (CMPX)

• Market cap: $359M
• 1 day: 0.38%
• 5 days: 31.82%
• 1 month: 72.85%
• 3 months: 41.08%
• 6 months: 161.00%
• Year to date: 86.43%
• 1 year: 80.00%
• 5 years: -34.42%
• 10 years: -34.42%
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic Substances

About: Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to broadly drug the immune system and identify optimal combinations empirically. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of three product candidates, CTX-009, CTX-471, and CTX-8371.

Employees: 32

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

81% more capital invested

Capital invested by funds: $93.6M [Q2] → $170M (+$76.1M) [Q3]

47% more repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 19

0% more funds holding in top 10

Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]

0.61% less ownership

Funds ownership: 67.65% [Q2] → 67.03% (-0.61%) [Q3]

4% less funds holding

Funds holding: 82 [Q2] → 79 (-3) [Q3]

14% less first-time investments, than exits

New positions opened: 12 | Existing positions closed: 14

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $10 283% upside
• Avg. target: $21 705% upside
• High target: $32 1,126% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Joseph Pantginis 30% 1-year accuracy 118 / 399 met price target	283% upside $10	Buy Reiterated	10 Jan 2025
D. Boral Capital Jason Kolbert 39% 1-year accuracy 76 / 193 met price target	1,126% upside $32	Buy Maintained	8 Jan 2025